Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bellone

Showing results (101-110 of 106) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 106 results.
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
British Journal of Cancer|June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapyS Bellone, R Tassi, M Betti, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)S Bellone, D M Roque, E R Siegel, et al.
Pageof 11

Showing results (101-110 of 106) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 106 results.
British Journal of Cancer|August 12, 2010
hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinomaE Cocco, Z Hu, C E Richter, et al.
British Journal of Cancer|June 19, 2009
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancerE Cocco, S Bellone, K El-Sahwi, et al.
British Journal of Cancer|November 19, 2009
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinomaK El-Sahwi, S Bellone, E Cocco, et al.
British Journal of Cancer|June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapyS Bellone, R Tassi, M Betti, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 1, 2021
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)S Bellone, D M Roque, E R Siegel, et al.
Pageof 11